A randomized, phase IIa exploratory trial to assess the safety and preliminary efficacy of LEO 43204 in patients with actinic keratosis
Files
Date
2016
Authors
Sinnya, S.
Tan, J.M.
Prow, T.W.
Primiero, C.
McEniery, E.
Selmer, J.
Østerdal, M.L.
Soyer, H.P.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
British Journal of Dermatology, 2016; 174(2):305-311
Statement of Responsibility
Conference Name
Abstract
Background: LEO 43204 is a novel ingenol derivative in development for the treatment of actinic keratosis.
Objectives: To compare the safety and preliminary efficacy of three doses of LEO43204 with ingenol mebutate in actinic keratoses (AKs).
Methods: Patients with at least three visible, discrete, nonkeratotic AKs on four separate selected treatment areas on the forearms received LEO 43204 gel (0·025%,0·05% and 0·075%) and ingenol mebutate 0·05% gel, by investigator-blinded,randomized allocation, for 2 consecutive days. Patients were assessed at 8 weeks.Primary outcomes included maximum composite local skin response (LSR) score and adverse events (AEs). Secondary outcomes included a reduction in the number of visible AKs.
Results: Forty patients completed the trial. For all treatments, mean LSR scores peaked at week 1, and were below baseline by week 8. Mean maximum composite LSR scores for LEO 43204 0·025%, 0·05% and 0·075% were 9·2 (Dunnett adjusted P = 0·02), 10·1 (Dunnett adjusted P = 0·90) and 11·2 (Dunnett adjusted P < 0·01), respectively, vs. ingenol mebutate 0·05% gel (10·0). The most frequent AEs across all treatments were application site pruritus, burning sensation and tenderness. Mean reduction in the number of AKs was comparable for ingenol mebutate and the two lowest doses of LEO 43204 (71·9–73·1%), but LEO 432040·075% gave a significantly larger reduction (81·8%; Dunnett adjusted P = 0·04).
Conclusions LEO 43204 had a similar safety profile to ingenol mebutate and a dose–response relationship for LSRs was demonstrated. The highest LEO 43204 dose (0·075%) significantly reduced the AK count when compared with ingenol mebutate
School/Discipline
Dissertation Note
Provenance
Description
Data source: Supporting information, http://onlinelibrary.wiley.com/doi/10.1111/bjd.14245/abstract;jsessionid=B972C99908AE424923EBC2C0F27750FF.f03t01#footer-support-info
Access Status
Rights
Copyright 2015 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. (https://creativecommons.org/licenses/by-nc-nd/4.0/)